Zacks Investment Research upgraded shares of Recro Pharma (NASDAQ:REPH) from a hold rating to a buy rating in a research note issued to investors on Thursday, Zacks.com reports. Zacks Investment Research currently has $11.00 target price on the specialty pharmaceutical company’s stock.

According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “

Several other analysts have also commented on the company. Roth Capital reaffirmed a buy rating on shares of Corvus Gold in a report on Monday, March 25th. ValuEngine raised XOMA from a sell rating to a hold rating in a report on Friday, May 24th. Finally, Oppenheimer raised their target price on Recro Pharma from $9.00 to $15.00 and gave the stock an outperform rating in a report on Thursday, April 4th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $11.30.

Recro Pharma stock opened at $10.04 on Thursday. Recro Pharma has a 52 week low of $5.07 and a 52 week high of $10.69. The business’s 50-day moving average is $9.73.

Recro Pharma (NASDAQ:REPH) last posted its earnings results on Friday, May 10th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.69. The firm had revenue of $25.07 million for the quarter, compared to analyst estimates of $20.51 million. Recro Pharma had a negative return on equity of 472.52% and a negative net margin of 83.56%. Analysts predict that Recro Pharma will post -0.54 EPS for the current year.

In other Recro Pharma news, Director Arnaud Ajdler purchased 40,000 shares of the stock in a transaction on Friday, May 17th. The shares were bought at an average price of $9.00 per share, for a total transaction of $360,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Geraldine Henwood sold 144,806 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $8.89, for a total value of $1,287,325.34. Following the transaction, the chief executive officer now owns 342,947 shares in the company, valued at approximately $3,048,798.83. The disclosure for this sale can be found here. Corporate insiders own 20.10% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. boosted its position in Recro Pharma by 5.7% during the fourth quarter. BlackRock Inc. now owns 1,154,815 shares of the specialty pharmaceutical company’s stock worth $8,199,000 after purchasing an additional 62,787 shares in the last quarter. Kennedy Capital Management Inc. boosted its position in Recro Pharma by 19.5% during the first quarter. Kennedy Capital Management Inc. now owns 598,107 shares of the specialty pharmaceutical company’s stock worth $3,505,000 after purchasing an additional 97,482 shares in the last quarter. Geode Capital Management LLC boosted its position in Recro Pharma by 12.3% during the fourth quarter. Geode Capital Management LLC now owns 157,953 shares of the specialty pharmaceutical company’s stock worth $1,121,000 after purchasing an additional 17,299 shares in the last quarter. Cadence Capital Management LLC purchased a new position in Recro Pharma during the first quarter worth approximately $803,000. Finally, Squarepoint Ops LLC boosted its position in Recro Pharma by 88.9% during the fourth quarter. Squarepoint Ops LLC now owns 81,794 shares of the specialty pharmaceutical company’s stock worth $581,000 after purchasing an additional 38,494 shares in the last quarter. Institutional investors own 56.99% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Read More: Support Level

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.